<DOC>
	<DOCNO>NCT01521962</DOCNO>
	<brief_summary>To determine efficacy safety SYR-322 ( alogliptin ) 25-mg , daily ( QD ) , patient diabetes use combination insulin .</brief_summary>
	<brief_title>Study Combination Therapy With SYR-322</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . The subject outpatient . 2 . The subject sign date write , informed consent form require privacy authorization prior initiation study procedure . 1 . The subject serious cardiac disease , serious cerebrovascular disorder , serious pancreatic hematological disease . 2 . The subject consider ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>